We separated the melanoma cell lines based on their driver mutation (BRAF V600E, NRAS Q61K/L, c-KIT or other), and found that LNK expression was significantly higher in cell lines that harbored BRAF and NRAS mutations (Fig. 1f), suggesting that hyperactivated RAS-RAF-MEK signaling may correlate with LNK expression in melanoma. The gene discussed is SH2B3; the disease is melanoma.